Biogen Idec Inc. (Nasdaq:BIIB) announced that new data, presented today at the 47th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, December 10-13, demonstrate that patients may benefit from earlier and consolidated use of ZEVALIN(R) (Ibritumomab Tiuxetan) radioimmunotherapy in refractory and hard-to-treat cancers, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular non-Hodgkin's lymphoma (FL).
